Global Myocardial Infarction Drugs Market 2016-2020

  • ID: 3633366
  • Report
  • Region: Global
  • 75 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • advanceCOR
  • Bayer HealthCare
  • Capricor
  • GSK
  • Novartis
  • RegeneRx
  • MORE
About Myocardial Infarction Drugs

Myocardial infarction, commonly known as heart attack, is the irreparable death of the heart tissue. It occurs when blood stops flowing to a part of the myocardium (heart muscle), depriving it of oxygen and nutrients. If the coronary artery that supplies blood to the heart muscle is blocked by the formation of plaque (a substance made of fat, cholesterol, and cellular waste), the heart is starved of oxygen, a condition called cardiac ischemia, causing tissue damage. Cardiac ischemia may lead to episodes of angina or chest pain. The slow build-up of plaque on the walls of the heart narrows the blood vessels and finally blocks them. Rapid flow of lipids through the vessels may also create a tear on the walls of the vessels causing aggregation of platelets and the formation of a clot. The clot formation causes obstruction of blood supply through the vessels, leading to necrosis or the death of tissues in the heart muscle.

The analysts forecast the global myocardial infarction drugs market to grow at a CAGR of 0.41% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global myocardial infarction drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of myocardial infarction.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Myocardial Infarction Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AstraZeneca
- Bayer HealthCare
- Eli Lilly
- Novartis
- Pfizer
- Sanofi

Other prominent vendors
- advanceCOR
- Armaron Bio
- Athersys
- BioVascular
- BMS
- Caladrius
- Capricor
- CSL Behring
- GNT Pharma
- GSK
- Ischemix
- Mesoblast
- NeuroVive
- Osiris Therapeutics
- PledPharma
- RegeneRx
- Teva Pharmaceuticals
- TiGenix
- US Stem Cell
- Ventrix

Market drivers
- Growing older population
- For a full, detailed list, view the full report

Market challenges
- Alternative therapies
- For a full, detailed list, view the full report

Market trends
- Growing awareness of disease
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • advanceCOR
  • Bayer HealthCare
  • Capricor
  • GSK
  • Novartis
  • RegeneRx
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
  • Key buying criteria
PART 05: Disease overview
  • Types of myocardial infarction
  • Pathophysiology
  • Risk factors
  • Diagnosis
  • Management
PART 06: Epidemiology and economic burden
  • Burden of disease
PART 07: Pipeline analysis
  • Canakinumab
  • MyoCell
  • MultiStem therapy
  • CLBS10
  • Prochymal
  • Revascor
  • CicloMulsion
  • PP-099
  • NP202
  • CAP-1002
  • Revacept
  • CSL112
PART 08: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 09: Market segmentation by drug class
  • Beta blockers
  • ACE inhibitors
  • ARBs
  • Vasodilators
  • Antithrombotic agents
  • Thrombolytics
  • Glycoprotein IIb/IIIa inhibitors
  • Anti-dyslipidemic drugs
  • Calcium channel blockers
  • Analgesics
PART 10: Market segmentation by EKG appearance
  • NSTEMI
  • STEMI
PART 11: Market segmentation by type
  • Brand-name drugs
  • Generic drugs
PART 12: Geographical segmentation
  • Global myocardial infarction drugs market segmentation by geography 2015-2020
  • Myocardial infarction drugs market in Americas
  • Myocardial infarction drugs market in EMEA
  • Myocardial infarction drugs market in APAC
PART 13: Market drivers
  • Increase in older population
  • Sedentary lifestyle
  • Rise in obesity
  • High prevalence of chronic conditions
PART 14: Impact of drivers

PART 15: Market challenges
  • Delayed diagnosis
  • Alternative therapies
  • Extensive use of generics
PART 16: Impact of drivers and challenges

PART 17: Market trends
  • Growing awareness of disease
  • Strategic alliances
  • Increased R&D
  • Prevalent use of stent grafts
PART 18: Vendor landscape
  • Competitive scenario
  • AstraZeneca
  • Bayer HealthCare
  • Eli Lilly
  • Novartis
  • Pfizer
  • Sanofi
  • Other prominent vendors
PART 19: Appendix
  • List of abbreviations
PART 20: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for myocardial infarction drugs
Exhibit 03: Pathophysiology of myocardial infarction
Exhibit 04: Risk factors of myocardial infarction
Exhibit 05: Diagnostic techniques for myocardial infarction
Exhibit 06: Treatment options for myocardial infarction
Exhibit 07: Projected prevalence of CVDs in US
Exhibit 08: Projected economic burden for CVDs in US
Exhibit 09: Pipeline portfolio: Myocardial infarction
Exhibit 10: Global myocardial infarction drugs market 2015-2020 ($ billions)
Exhibit 11: Five forces analysis
Exhibit 12: Global myocardial infarction drugs market segmentation by EKG appearance 2015
Exhibit 13: Global myocardial infarction drugs market segmentation by type 2015
Exhibit 14: Global myocardial infarction drugs market segmentation by geography 2015
Exhibit 15: Myocardial infarction drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 16: Myocardial infarction drugs market in Americas 2015-2020 ($ billions)
Exhibit 17: Myocardial infarction drugs market in EMEA 2015-2020 ($ billions)
Exhibit 18: Myocardial infarction drugs market in APAC 2015-2020 ($ billions)
Exhibit 19: Global myocardial infarction drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 20: Impact of drivers
Exhibit 21: Impact of drivers and challenges
Exhibit 22: AstraZeneca: Business segmentation by revenue 2014
Exhibit 23: AstraZeneca: Cardiovascular and metabolic diseases segment by revenue 2014
Exhibit 24: AstraZeneca: YoY revenue and growth rate of Crestor 2012-2014 ($ billions)
Exhibit 25: AstraZeneca: YoY revenue and growth rate of Seloken/Toprol 2012-2014 ($ millions)
Exhibit 26: AstraZeneca: YoY revenue and growth rate of Atacand 2012-2014 ($ millions)
Exhibit 27: AstraZeneca: YoY revenue and growth rate of Brilinta/Brilique 2012-2014 ($ millions)
Exhibit 28: AstraZeneca: Key takeaways
Exhibit 29: Bayer HealthCare: YoY revenue and growth rate of Xarelto 2012-2014 ($ millions)
Exhibit 30: Bayer HealthCare: YoY revenue and growth rate of Adalat 2012-2014 ($ millions)
Exhibit 31: Bayer HealthCare: Key takeaways
Exhibit 32: Eli Lilly: YoY revenue and growth rate of Effient (global) 2012-2015 ($ millions)
Exhibit 33: Eli Lilly: YoY revenue and growth rate of Effient in US 2012-2015 ($ millions)
Exhibit 34: Eli Lilly: YoY revenue and growth rate of Effient in rest of world 2012-2015 ($ millions)
Exhibit 35: Eli Lilly: Key takeaways
Exhibit 36: Novartis: YoY revenue and growth rate of Diovan 2012-2015 ($ billions)
Exhibit 37: Novartis: YoY revenue and growth rate of Exforge 2012-2015 ($ billions)
Exhibit 38: Novartis: Key takeaways
Exhibit 39: Pfizer: YoY revenue and growth rate of Lipitor 2012-2014 ($ billions)
Exhibit 40: Pfizer: YoY revenue and growth rate of Norvasc 2012-2014 ($ billions)
Exhibit 41: Pfizer: YoY revenue and growth rate of Fragmin 2012-2014 ($ millions)
Exhibit 42: Pfizer: YoY revenue and growth rate of Caduet 2012-2014 ($ millions)
Exhibit 43: Pfizer: Key takeaways
Exhibit 44: Sanofi: YoY revenue and growth rate of Plavix 2012-2014 ($ billions)
Exhibit 45: Sanofi: YoY revenue and growth rate of Lovenox 2012-2014 ($ billions)
Exhibit 46: Sanofi: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • advanceCOR
  • Bayer HealthCare
  • Capricor
  • GSK
  • Novartis
  • RegeneRx
  • MORE
New Report Released: – Global Myocardial Infarction Drugs Market 2016-2020

The author of the report recognizes the following companies as the key players in the Global Myocardial Infarction Drugs Market: AstraZeneca, Bayer HealthCare, Eli Lilly, Novartis, Pfizer, and Sanofi.

Other Prominent Vendors in the market are: advanceCOR, Armaron Bio, Athersys, BioVascular, BMS, Caladrius, Capricor, CSL Behring, GNT Pharma, GSK, Ischemix, Mesoblast, NeuroVive, Osiris Therapeutics, PledPharma, RegeneRx, Teva Pharmaceuticals, TiGenix, US Stem Cell, and Ventrix.

Commenting on the report, an analyst from the research team said: “Enhanced patient awareness is expected to lead to early disease diagnosis and treatment. The World Heart Federation along with Bupa, MOVEWeek, the European Healthy Stadia Network, and Days of the Year organizes 29th September of every year as the World Heart Day. Heart Day campaigns are organized to spread awareness about heart diseases. These campaigns are sponsored by Amgen, AstraZeneca, Bupa, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Pfizer, and Unilever.”

According to the report, in older people, plaque accumulation in the arteries increases because of the loss of elasticity of the blood vessels. Drugmakers are realizing that an aging population will have significant impact on their business. Increasing number of patients plus lucrative pricing equals big growth for the market.

Further, the report states that the availability of effective surgical treatments and the use of catheter-based interventions pose a challenge to the growth of the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- AstraZeneca
- Bayer HealthCare
- Eli Lilly
- Novartis
- Pfizer
- Sanofi
- advanceCOR
- Armaron Bio
- Athersys
- BioVascular
- BMS
- Caladrius
- Capricor
- CSL Behring
- GNT Pharma
- GSK
- Ischemix
- Mesoblast
- NeuroVive
- Osiris Therapeutics
- PledPharma
- RegeneRx
- Teva Pharmaceuticals
- TiGenix
- US Stem Cell
- Ventrix.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll